Experimental pancreatic cancer pill shows major survival gain

A rare bright result in one of cancer’s hardest settings

An experimental drug called daraxonrasib has delivered the kind of result pancreatic cancer research rarely produces: a sizable survival improvement in patients with metastatic disease after chemotherapy stopped working. According to the supplied source text, patients taking the daily pill survived 13.2 months on average, compared with 6.7 months for those continuing standard chemotherapy infusions.

That difference is why outside experts quoted in the source described the result in unusually strong terms. Pancreatic cancer remains one of the most aggressive and difficult-to-treat forms of cancer, and the text notes that most people with advanced disease survive only around three to six months on average even with standard treatment. In that context, extending average survival into the 13-month range would represent a major shift.

The study involved 500 people with metastatic pancreatic cancer across the US, Europe, and Asia, all of whom had stopped responding to an initial round of chemotherapy. Participants were assigned either to daily daraxonrasib or to continued chemotherapy infusions. The results were presented at the American Society of Clinical Oncology meeting in Chicago on May 31.

The underlying biological target helps explain the enthusiasm. The source text says more than 90 percent of pancreatic cancers are driven by mutations in the KRAS gene, which produces the K-Ras protein. When mutated, that protein remains stuck in a state that drives uncontrolled cell division. Daraxonrasib is described as binding to the protein in an effort to dampen its signals and slow cancer growth.

That matters because KRAS-driven cancers have long been a major challenge in oncology. If the reported results hold up, the drug may not just be a useful new therapy. It may also be evidence that a common and historically difficult cancer driver can be targeted in a way that changes patient outcomes in a particularly lethal disease.

Another notable point in the supplied material is tolerability. The source says the pill had fewer side effects than standard chemotherapy. In advanced pancreatic cancer, that is not a secondary detail. Extra months of survival carry more value when they are not bought entirely through additional treatment burden. The convenience of a daily pill compared with repeated infusion-based chemotherapy also changes the treatment experience in practical ways.

Caution is still warranted. Conference presentations are not the same thing as long-term clinical adoption, and major cancer findings typically face intense follow-up scrutiny over durability, safety, subgroup effects, and real-world use. But the result stands out because pancreatic cancer has resisted progress for so long that even moderate gains draw attention. A near doubling of average survival is in a different category.

For patients and clinicians, the broader significance is simple. Pancreatic cancer has been defined by late diagnosis, poor prognosis, and limited options. A therapy that meaningfully improves survival after first-line chemotherapy failure would open an important new treatment window in a disease where those windows are usually narrow. That is why this result is already being framed as more than incremental.

Why the study stands out

• The trial involved 500 patients with metastatic pancreatic cancer after chemotherapy failure.
• Average survival was reported at 13.2 months with daraxonrasib versus 6.7 months with chemotherapy.
• The treatment was also described as having fewer side effects than standard chemotherapy.

This article is based on reporting by New Scientist. Read the original article.